TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11174744

Group type: EXPERIMENTAL
Intervention: alpha-stat
Number of subjects: 168

Group type: COMPARATOR
Intervention: pH-stat
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: alpha-stat and pH-stat
Number of subjects: 168
Study: 11090583

Group type: EXPERIMENTAL
Intervention: Head-down tilt during Exercise treatment (15 min cycling at 70% maximal O2 uptake)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-up tilt during Exercise treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-up tilt during No-Exercise treatment (30 min resting)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-down tilt during No-Exercise treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Head-down tilt compared to head-up tilt
Number of subjects: 6
Study: 12206029

Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice (0.454% stannous fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 0
Study: 8476620

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine 1.5 mg/kg (Group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiopental 3 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 4)
Number of subjects: 48
Study: 3510638

Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g every four hours for four doses)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Moxalactam (2 g every four hours for four doses)
Number of subjects: 118
Study: 29792554

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg three times a day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Methazolamide (100 mg twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 27389034

Group type: EXPERIMENTAL
Intervention: CAFAP intervention (8 weeks duration)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 56
Study: 24013268

Group type: EXPERIMENTAL
Intervention: Individualised dual-task home-based programme performed six days a week for seven weeks.
Number of subjects: 16
Study: 22710649

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil/chlorthalidone 40/25 mg
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil/chlorthalidone 80/25 mg
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Olmesartan/hydrochlorothiazide 40/25 mg
Number of subjects: 1071
Study: 19748210

Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach (Group I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transperitoneal approach (Group II)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transperitoneal approach (Group III)
Number of subjects: 34
Study: 18617877

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: White Portland cement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fuji Ortho
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silver amalgam
Number of subjects: 50
Study: 16544870

Group type: EXPERIMENTAL
Intervention: Home health exercise and problem solving intervention (Reducing Disability in Alzheimer's Disease, or RDAD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12428818

Group type: EXPERIMENTAL
Intervention: Alexander Technique
Number of subjects: 93

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 93

Group type: COMPARATOR
Intervention: No additional intervention
Number of subjects: 93
Study: 10600919

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat with preload of banana shake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK‐A receptor antagonist) with intraduodenal fat and preload of banana shake
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline with preload of banana shake
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline perfusion with preload of banana shake
Number of subjects: 24
Study: 8949807

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine at L3-4 interspace (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine at L4-5 interspace (n=15)
Number of subjects: 30
Study: 1771945

Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 100 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30256796

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 1431
Study: 27566855

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly (extra-large group, PEDs ≥352 μm)
Number of subjects: 1097
Study: 25061716

Group type: COMPARATOR
Intervention: Control Formula (CF)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Formula supplemented with 8 g GOS/L (EF8)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Human Milk (HM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Formula supplemented with 4 g GOS/L (EF4)
Number of subjects: 180
Study: 22143621

Group type: EXPERIMENTAL
Intervention: Low-energy-dense (LE) foods (30 kcal per 100 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-energy-dense (HE) foods (130 kcal per 100 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Food texture (liquid or semi-solid)
Number of subjects: 27
Study: 20381802

Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 80
Study: 18410231

Group type: EXPERIMENTAL
Intervention: Moderately high salt intake (11.2 g/d) with high calcium diet (1284 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderately low calcium intake (518 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderately high salt intake (11.2 g/d) with low calcium diet (518 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderately low salt intake (3.9 g/d) with low calcium diet (518 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderately low salt intake (3.9 g/d) with high calcium diet (1284 mg)
Number of subjects: 11
Study: 17221036

Group type: EXPERIMENTAL
Intervention: Clonidine (0.8 microg/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (0.9% saline solution)
Number of subjects: 62
Study: 12811320

Group type: EXPERIMENTAL
Intervention: Flavored Colyte
Number of subjects: 130

Group type: COMPARATOR
Intervention: Unflavored Colyte
Number of subjects: 130
Study: 11286044

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 22
Study: 8978953

Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SSc)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study: 1449200

Group type: EXPERIMENTAL
Intervention: Standard regimen of four (40 ml) or eight (80 ml) ampules of antivenom
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Three Brazilian polyspecific antivenoms
Number of subjects: 118
Study: 6731758

Group type: EXPERIMENTAL
Intervention: Electrostimulation anesthesia combined with nitrous oxide (ESA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inhalation anesthesia with enflurane-nitrous oxide (EFL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (ESA and EFL)
Number of subjects: 22
Study: 30606240

Group type: EXPERIMENTAL
Intervention: Non-linear periodized resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional non-periodized resistance training
Number of subjects: 0
Study: 30503595

Group type: EXPERIMENTAL
Intervention: CoreValve (CV)
Number of subjects: 675

Group type: COMPARATOR
Intervention: SAPIEN XT (SXT)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Evolut R (ER)
Number of subjects: 675

Group type: COMPARATOR
Intervention: SAPIEN 3 (S3)
Number of subjects: 675
Study: 25193570

Group type: EXPERIMENTAL
Intervention: Operative procedures
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conservative procedures
Number of subjects: 36
Study: 25341445

Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Plain language summary
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transcript
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Abstract
Number of subjects: 36
Study: 21543992

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Medical therapy (prostaglandin analog)
Number of subjects: 69
Study: 21180796

Group type: EXPERIMENTAL
Intervention: Lateral compaction (LC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tagger's hybrid (TH)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MicroSeal (MS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GuttaFlow (GF)
Number of subjects: 52
Study: 17878467

Group type: EXPERIMENTAL
Intervention: Bronchodilators (beta(2)-agonists and anticholinergics), including once-a-day preparations and combination products with inhaled steroids.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents under development for COPD.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatments.
Number of subjects: 0
Study: 16271677

Group type: EXPERIMENTAL
Intervention: Ultrasonographic-guided approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional landmark approach
Number of subjects: 60
Study: 11907489

Group type: EXPERIMENTAL
Intervention: Topical administration of 0.1% 8-methoxypsoralen cream
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical administration of 3 mg/L 8-methoxypsoralen bath
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral administration of 0.6 or 1 mg/kg 8-methoxypsoralen
Number of subjects: 8
Study: 9485534

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7842186

Group type: EXPERIMENTAL
Intervention: Uniphyl (theophylline), once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 micrograms four times per day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of Uniphyl and salbutamol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2218718

Group type: EXPERIMENTAL
Intervention: Active group (pulsed electromagnetic fields)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 195
Study: 365289

Group type: EXPERIMENTAL
Intervention: Standard drug treatment plus intermittent positive-pressure ventilation (IPPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard drug treatment alone
Number of subjects: 0
Study: 31050982

Group type: EXPERIMENTAL
Intervention: Extracorporeal Magnetic Innervation (ExMI) therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: No therapeutic intervention (Control group)
Number of subjects: 52
Study: 29349982

Group type: COMPARATOR
Intervention: 20 ml physiological saline (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10 ml tranexamic acid and 10 ml physiological saline (Group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 20 ml physiological saline (Group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10 ml tranexamic acid and 10 ml physiological saline (Group D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study: 26849923

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (MMF) (Group B)
Number of subjects: 60
Study: 23681364

Group type: EXPERIMENTAL
Intervention: AZD9773 cohort 1 (250/50 U/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AZD9773 cohort 2 (500/100 U/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21281874

Group type: EXPERIMENTAL
Intervention: Novo-Helisen Depot, A alternata 100%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19566116

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Cyclosporin withdrawal
Number of subjects: 536

Group type: COMPARATOR
Intervention: Standard-dose cyclosporin
Number of subjects: 536
Study: 16565000

Group type: EXPERIMENTAL
Intervention: Foldable iris-claw phakic intraocular lens (pIOL) implantation
Number of subjects: 41
Study: 12647600

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d; n = 5,170)
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care (n = 5,185)
Number of subjects: 10355

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study: 10579150

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg with bupropion SR 300 mg (two 150 mg tablets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bupropion SR 300 mg alone (two 150 mg tablets)
Number of subjects: 24
Study: 8916632

Group type: EXPERIMENTAL
Intervention: Emotionally focused therapy (EFT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 32
Study: 1886157

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy (2 or 5 years)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Control (no adjuvant endocrine therapy)
Number of subjects: 1846
Study: 6229567

Group type: EXPERIMENTAL
Intervention: 25% reduction in lithium dosage
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 50% reduction in lithium dosage
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual dose of lithium (control)
Number of subjects: 72
Study: 30394541

Group type: EXPERIMENTAL
Intervention: Bolstered standard of care (BSOC) services plus an economic-strengthening intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolstered standard of care (BSOC) services
Number of subjects: 0
Study: 28182510

Group type: EXPERIMENTAL
Intervention: Low-volume plyometric training (LPT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-volume plyometric training (HPT)
Number of subjects: 25
Study: 27084661

Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Number of subjects: 69
Study: 25438482

Group type: EXPERIMENTAL
Intervention: NitroSense Derma Protect patch (24 mg, releasing 9 nmol/cm2/min of nitric oxide for 3 hours every other day for 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NitroSense Derma Protect patch
Number of subjects: 50
Study: 22438367

Group type: EXPERIMENTAL
Intervention: IMNCI programme implementation
Number of subjects: 59680

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59680
Study: 19497197

Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17615018

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Brief intervention by dental professionals providing feedback on oral symptoms and dental treatments relevant to smoking.
Number of subjects: 797

Group type: COMPARATOR
Intervention: Nonintervention Group (NG) - No intervention provided.
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: All patients (IG and NG combined)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Patients not ready to quit (IG and NG combined)
Number of subjects: 797
Study: 14767365

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS) monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard sedation assessment using Ramsay score
Number of subjects: 0
Study: 11956262

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 60 mg/m² on days 1, 8, and 15 repeated every 4 weeks (group 1; n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m² on days 1 and 15 of a 4-week cycle (group 2; n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall treatment with oxaliplatin
Number of subjects: 32
Study: 10450425

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis against Plasmodium falciparum malaria
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo only or placebo and iron supplementation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis alone or in combination with iron
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 106
Study: 7541448

Group type: EXPERIMENTAL
Intervention: Lenograstim (5 micrograms/kg/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 120
Study: 2473880

Group type: EXPERIMENTAL
Intervention: Deviant stimuli presented at angles of 10, 45, or 90 degrees to the right of the standards.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard stimuli presented directly in front of the subjects.
Number of subjects: 12
Study: 795372

Group type: EXPERIMENTAL
Intervention: Ticarcillin + Cephalothin or Gentamicin
Number of subjects: 127
Study: 31687762

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (LDER)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: All treatments (HDER, LDER, Warfarin)
Number of subjects: 21105
Study: 28597176

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist monitoring with CARAT questionnaire every 2 weeks and counselling on disease management, ICS adherence, and inhalation technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Pharmacist monitoring
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electronic Monitoring Intervention (EMI) users
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (CG) - Standard care without pharmacist monitoring
Number of subjects: 80
Study: 26009784

Group type: EXPERIMENTAL
Intervention: Behavioral programs (Comet, Cope, Incredible Years)
Number of subjects: 908

Group type: COMPARATOR
Intervention: Nonbehavioral program (Connect)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Parenting interventions (all programs)
Number of subjects: 908
Study: 23916584

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polypropylene mesh surgery (group II)
Number of subjects: 40
Study: 21168122

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19573556

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (250 mg) plus Vitamin B12 (100 microg), folic acid (300 microg), Vitamin B6 (12.5 mg) and l‐arginine (100 mg) daily for 1 year
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 65
Study: 17380560

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) and graduated compression (GC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 14679114

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus gemcitabine-cisplatin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin alone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus gemcitabine-cisplatin (HER2 3+ or FISH-positive subgroup)
Number of subjects: 103
Study: 11119461

Group type: EXPERIMENTAL
Intervention: Multisite atrial pacing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Right atrial pacing
Number of subjects: 20
Study: 9211444

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7957512

Group type: EXPERIMENTAL
Intervention: M(r) 2264 Cl 2 x 5 mg i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 2 x 10 mg i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3054373

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, surgery, postoperative radiotherapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional treatment (surgery and postoperative radiotherapy)
Number of subjects: 158
Study: 4583181

Group type: EXPERIMENTAL
Intervention: Breast milk substitute
Number of subjects: 0
Study: 29162290

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention using the 'Good Palliative‐Geriatric Practice' algorithm and STOPP/START criteria
Number of subjects: 490

Group type: COMPARATOR
Intervention: Routine standard of care (Control group)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 490
Study: 28663392

Group type: EXPERIMENTAL
Intervention: Trabecular Metal (TM) acetabular component
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cemented acetabular component
Number of subjects: 42
Study: 25873093

Group type: EXPERIMENTAL
Intervention: mHealth intervention (free phone communication, data submission, motivational messages)
Number of subjects: 3825

Group type: EXPERIMENTAL
Intervention: Participatory community engagement arm
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 3825
Study: 23968849

Group type: EXPERIMENTAL
Intervention: Multimodal neuropsychological intervention (attention retraining, teaching compensatory strategies, psychoeducation, psychological support, and homework assignments) conducted once a week in 60-minute sessions during thirteen consecutive weeks
Number of subjects: 98